Please login to the form below

Not currently logged in
Email:
Password:

Valeant appoints Joseph Papa to end CEO uncertainty

He will take over from Michael Pearson at the troubled pharma company in May

Valeant Joseph PapaValeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May.

Papa will also take on the chairman's role and join the Canadian pharmaceuticals company's board of directors, taking Pearson's place as a director on the board.

Robert Ingram, Valeant's chairman of the board, said: “The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time.

“He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms.”

Papa will join a troubled company that last month cut its revenue forecasts for 2016 and reported a fourth-quarter loss. The firm also missed the deadline for filing its 10k 2015 annual report and said last week that this should now be filed by 29 April.

To help him bring it back on-course Papa brings over 35 years of leadership and operations experience in the pharmaceutical and healthcare industries to the firm, including 20 years of branded prescription drug experience.

He moves to Valeant from his most recent role as chief executive officer and chairman of the board at Perrigo Company, the Dublin-based global healthcare supplier, which he has occupied since 2006.

Prior to Perrigo, Papa served as chairman and chief executive officer of Cardinal Health's pharmaceutical and technologies services segment between 2004 and 2006, having joined from Watson Pharmaceuticals where he had served as president and chief operating officer from 2001.

During his 35 year career in pharmaceuticals, Papa has also held management positions at DuPont Pharmaceuticals, G.D. Searle & Company, Novartis and Pharmacia Corporation.

He said: “I am excited to take on the challenge of leading Valeant and helping the company chart a new course.

“We have an opportunity to move forward with a renewed focus on operating with integrity across all areas of the business and providing customers with safe and affordable products that improve their lives."

26th April 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics